Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Supriya Lifescience Limited (SUPRIYA) Stock Price & Analysis

0 Followers

SUPRIYA Stock Chart & Stats

â‚ą637.80â‚ą5.70(0.90%)
At close: 3:30 PM GMT+5:30
â‚ą700â‚ą800â‚ą900â‚ą1KAug 17Aug 31Sep 15Sep 28Oct 12Oct 26Nov 9
Day’s Range
INR 622.10 - INR 663.70
52-Week Range
INR 545.65 - INR 1,085.50
Previous Close
INR 632.10
Volume
N/A
Average Volume (3M)
20.81K
Market Cap
INR 50.87B
Enterprise Value
INR 75.83B
Total Cash (Recent Filing)
INR 788.67M
Total Debt (Recent Filing)
INR 0
Price to Earnings (P/E)
25.9
Beta
0.72
Next Earnings
Feb 16, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Sep 04, 2026
Dividend Yield
0.16%

Bulls Say, Bears Say

Bulls Say

Strong Revenue Expansion

Sustained revenue expansion indicates improving demand for the company’s API portfolio and a recovery from the prior decline. Continued top-line growth can improve manufacturing utilization, support operating leverage, and provide a durable base for funding product and market development.

Very Low Leverage

A conservatively financed balance sheet reduces financial risk and interest burden, giving Supriya greater flexibility through changes in demand or profitability. Strong equity growth and minimal leverage also support internally funded investment and preserve capacity for future strategic decisions.

Improving Cash Generation

The recent improvement in operating and free cash flow strengthens earnings quality and increases the company’s ability to fund operations and investment internally. If maintained, this cash conversion can reduce reliance on external financing and support more resilient growth over coming quarters.

Bears Say

Margin And Earnings Volatility

Profitability has not followed a consistently stable path, which can make future earnings less predictable even when revenue is growing. Fluctuations associated with product mix, pricing, or costs may limit operating leverage and require careful management to preserve margins as the business scales.

Historically Inconsistent Free Cash Flow

The earlier periods of negative free cash flow show that reported operating performance has not always translated into dependable cash generation. Investment requirements or working-capital swings could recur, potentially reducing funds available for expansion and making internal financing less consistent.

Earnings Growth Lag

Negative EPS growth indicates that per-share earnings have recently contracted despite the company’s broader revenue expansion. This suggests that sales growth has not fully converted into bottom-line improvement, leaving profitability and shareholder earnings dependent on better margins, costs, or product mix.

Supriya Lifescience Limited News

SUPRIYA FAQ

What was Supriya Lifescience Limited’s price range in the past 12 months?
Supriya Lifescience Limited lowest stock price was â‚ą545.65 and its highest was â‚ą1085.50 in the past 12 months.
What is Supriya Lifescience Limited’s market cap?
Supriya Lifescience Limited’s market cap is ₹50.87B.
When is Supriya Lifescience Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Supriya Lifescience Limited’s earnings last quarter?
Supriya Lifescience Limited released its earnings results on Nov 06, 2026. The company reported â‚ą3.6 earnings per share for the quarter, missing the consensus estimate of â‚ą5 by -â‚ą1.4.
Is Supriya Lifescience Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Supriya Lifescience Limited pay dividends?
Supriya Lifescience Limited pays an annual dividend of â‚ą1 which represents an annual dividend yield of 0.16%. See more information on Supriya Lifescience Limited dividends here
What is Supriya Lifescience Limited’s EPS estimate?
Supriya Lifescience Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Supriya Lifescience Limited have?
Supriya Lifescience Limited has 80,482,800 shares outstanding.
What happened to Supriya Lifescience Limited’s price movement after its last earnings report?
Supriya Lifescience Limited reported an EPS of â‚ą3.6 in its last earnings report, missing expectations of â‚ą5. Following the earnings report the stock price went down -19.956%.
Which hedge fund is a major shareholder of Supriya Lifescience Limited?
Currently, no hedge funds are holding shares in IN:SUPRIYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology